Ob/Gyn Medical News about Topotecan

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: Results of a single-institutional phase II study
Gynecologic Oncology, 06/30/09

Kang H et al. - The relative high-dose of topotecan combined with carboplatin was feasible and produced modest activity in recurrent or persistent EOC. The RR and survival data appear promising for the initially platinum-sensitive cohort and thus this regimen may be considered for further development in this patient.

<< Previous
Secondary cytoreductive surgery in patients presenting with...

Next >>
A detailed analysis of the learning curve: Robotic hysterectomy...

Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3 mediated Bid cleavage
Journal of Pharmacology and Experimental Therapeutics, 10/14/09 Relevance Score: 82%

Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia
Cancer, 11/06/09 Relevance Score: 80%

Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: Pharmacological rationale and clinical response
Pediatric Blood & Cancer, 10/27/09 Relevance Score: 80%

Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: childrens oncology group study d9803
Journal of Clinical Oncology, 10/08/09 Relevance Score: 80%